PE Fund Investments
Enzene Biosciences raises $50-M from Eight Roads, F-Prime Capital, others
Pune-based Enzene Biosciences Ltd has raised USD 50 million from its publicly listed parent company Alkem Laboratories and Private Equity investors, Eight Roads Ventures and F-Prime Capital. The fresh funds will be used to enhance manufacturing capabilities and drive expansion plans both in India and in the US. The firm has a 400-persons team. Enzene has developed a captive pipeline of biosimilars. These have been out-licensed to pharmaceutical companies across global markets while also offering end-to-end contract development and manufacturing (CDMO) services to biotechnology companies. Enzene has commercialised four biosimilars in India and has another fourteen products in the pipeline at various stages of development. Many of its in-market and pipeline products have already been partnered for commercial rights in emerging and regulated markets.
Want to receive such news items in your inbox? Click Here to sign up for a trial.
